概括
冰是一种纯粹的甲基胺化物形式,由于其纯度和可吸入的形式,具有重大危险. 这种强烈的精神兴奋剂提供长时间的效果,与可卡因不同,并且是非法合成的.
科学领域:
- 药理学 药理学是指药理学的学科.
- 神经科学是一个神经科学.
- 公共卫生 公共卫生
背景情况:
- 冰是一种高度纯净的甲基胺化物形式,正在成为一种重要的滥用药物.
- 它的吸入式施用途径导致强烈的精神刺激作用,与静脉注射剂量相当.
研究的目的:
- 描述冰的特性和危害 (甲基胺化物).
- 将其影响和滥用潜力与可卡因进行比较.
主要方法:
- 审查现有的关于甲基胺及其滥用的文献.
- 甲基胺和可卡因机制的药理比较和作用时间.
主要成果:
- 冰的纯度和吸入性增加了它的危险性和滥用潜力.
- 与可卡因 (分钟) 相比,甲基胺的兴奋剂效应延长 (小时).
- 甲基胺是一种在国内非法实验室制造的合成化合物.
结论:
- 冰代表了一种危险的甲基胺滥用形式,其特点是高纯度和强烈的长期影响的快速发作.
- 它的滥用特征与可卡因有相似之处,包括强迫性使用,但具有不同的药理动力学和合成来源.
- 国内非法制造甲基胺有助于其可访问性和公共卫生威胁.
相关概念视频
Oral Drug Delivery Systems: Introduction
Oral drug delivery is the most common route of administration due to its convenience, cost-effectiveness, and high patient compliance. It enables precise formulation to ensure proper drug dosage and bioavailability. The development of oral dosage forms considers drug properties such as solubility, stability, and absorption to optimize therapeutic efficacy.Tablets, capsules, liquids, and chewable formulations enhance drug stability, mask undesirable tastes, and improve patient experience.
Drug Delivery: Miscellaneous Routes
Drug delivery methods like oral inhalation, nasal sprays, transdermal patches, eye drops, intravitreal injection, and rectal administration provide localized effects with reduced toxicity.
Oral inhalation and nasal sprays swiftly transfer drugs across the respiratory epithelium's mucosal layer. Inhaled glucocorticoids and bronchodilators directly target lung conditions such as asthma, while fluticasone nasal spray mitigates allergic rhinitis.
Transdermal patches transport drugs through the...
Oral inhalation and nasal sprays swiftly transfer drugs across the respiratory epithelium's mucosal layer. Inhaled glucocorticoids and bronchodilators directly target lung conditions such as asthma, while fluticasone nasal spray mitigates allergic rhinitis.
Transdermal patches transport drugs through the...
Drug Delivery Systems: Different Types
Conventional oral drug products, termed immediate-release (IR) formulations, are engineered to promptly release their active pharmaceutical ingredient (API) upon ingestion, typically in tablets or capsules. This rapid release often results in swift drug absorption and consequent pharmacodynamic effects, although the timing and intensity can vary depending on the drug's properties. Prodrugs within these formulations require metabolic conversion to activate their pharmacodynamic effects,...
IV Infusion to Oral Dosing: Conversion Methods
The development of extended-release formulations has facilitated the transition from intravenous to oral medication, offering a more convenient and patient-friendly approach to drug administration. This transition, however, requires careful management to ensure that therapeutic drug levels are maintained, preserving efficacy and avoiding adverse effects. Understanding pharmacokinetic principles and dosage calculations is critical during this process.Pharmacokinetics of the...
Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence
Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...
Modified-Release Drug Delivery Systems: Overview
Modified-release dosage forms are designed to address the limitations of drugs with short biological half-lives. These forms maintain stable therapeutic drug concentrations over extended periods, reducing the need for frequent dosing. A consistent drug level helps minimize peak-trough fluctuations, which can reduce adverse effects, lower the risk of drug resistance, and improve overall treatment effectiveness.One common type of modified-release form is the extended-release (ER) formulation. ER...

